While CEO and COO open-market buys are strong signals, their absence isn't fatal. In Fiserv's case, recent buys from the new CFO, Chief Legal Officer, and a director with a history of successful insider trades provide critical, albeit more nuanced, confirmation of a turnaround from key oversight roles.

In biotech, CEO insider buys are common and not very predictive. The real signal comes from the rest of the management team, especially the CFO. CFOs are typically more bearish and financially disciplined, so their decision to buy company stock is a particularly strong vote of confidence.

Despite massive stock price drops, there is a notable lack of significant insider buying at many SaaS companies. This passivity suggests management and boards may not believe a quick recovery is imminent, preferring to wait for an "all clear" signal before deploying their own capital.

To avoid chasing bubble-era valuations, they first vet stocks against M&A comps, then apply a second, absolute cheapness test (an 'owner earnings yield' over 8%). This second filter protects them from extrapolating irrational purchase multiples driven by low interest rates or market exuberance.

Insider buying in biotech isn't just a short-term trading signal around an event. The quantitative analysis shows its predictive power lasts for months after the transaction. This implies insiders are buying based on a durable, fundamental belief in the company's science and trajectory, not just upcoming news.

The HUMM Group board delayed disclosing a superior third-party takeover bid until after an activist challenge. This strategic timing served to "cleanse" the chairman of material non-public information, legally permitting him to immediately buy more shares and entrench his position.

Empirical studies show that the strongest investment returns don't come from insider buying or value investing in isolation. The key is the combination: systematically buying stocks that exhibit C-suite insider purchasing and also rank in the cheapest deciles based on quantitative value metrics.

When screening for insider activity, purchases by the Chief Financial Officer (CFO) may warrant special attention. Academic research indicates that CFOs, perhaps due to deeper financial acumen and risk awareness, have historically achieved better investment results on their personal stock purchases compared to CEOs.

Insiders and CEOs are generally good at timing capital allocation, issuing shares when prices are high and buying back when low. The current lack of equity issuance from high-flying tech companies suggests their leadership doesn't view their stock as overvalued, despite having clear reasons to raise capital.